Prostaglandin E2, prostaglandin I2 and the vascular changes of inflammation

British Journal of Pharmacology
T J Williams

Abstract

1. Plasma exudation and blood flow changes induced by intradermal injection of prostaglandins E2 (PGE2), I2 (PG12), D2 (PGD2) and F2 alpha (PGF2 alpha) were measured in rabbit dorsal skin by the use of [131I]-albumin and 133Xe. 2. Little plasma exudation was produced by any of the prostaglandins when injected alone. 3. Both PGE2 and PGI2 were potent at increasing blood flow, whereas PGF2 alpha and PGD2 produced an increase only at high doses. 4. All of the prostaglandins studied potentiated the plasma exudation induced by bradykinin. PGE2 and PGI2 had similar potent potentiating activity, whereas PGD2 and PGF2 alpha had activity at doses too high to be of biological significance. 5. Intradermal injections of arachidonate alone resulted in little plasma exudation but produced an increase in blood flow. Arachidonate potentiated bradykinin-induced plasma exudation. 6. Locally-injected indomethacin had no effect on basal blood flow and little effect on the exudation produced by bradykinin, but indomethacin did inhibit the vasodilatation and exudation potentiation produced by arachidonate. 7. PGE2 and PGI2 had similar potency in producing marked potentiation of plasma exudation induced by intradermal injection of zymosan. 8. In the ...Continue Reading

References

Dec 8, 1977·Nature·T J Williams, M J Peck
Oct 18, 1976·Biochemical and Biophysical Research Communications·W C ChangS Tsurufuji
Feb 1, 1976·British Journal of Pharmacology·R J FlowerW P Kingston
Mar 1, 1971·British Journal of Pharmacology·P Crunkhorn, A L Willis
Dec 13, 1972·Nature: New Biology·S H Ferreira
Mar 31, 1959·Acta Physiologica Scandinavica·S BERGSTROMJ SJOVALL

❮ Previous
Next ❯

Citations

Jun 1, 1988·Agents and Actions·E I HarperR A Brown
Oct 1, 1986·Agents and Actions·T J WilliamsP J Jose
Dec 1, 1981·Agents and Actions·J MorleyW Paul
Mar 1, 1985·Agents and Actions·S J Foster, M E McCormick
Aug 1, 1983·Agents and Actions·H Bult, A G Herman
Jun 1, 1990·Gastroenterologia Japonica·N KawadaS Morisawa
Aug 28, 2009·European Journal of Clinical Pharmacology·Helenie KefalakesGeorge Kolios
Mar 27, 2012·Rheumatology International·Samuel Joshua PragasamMahaboobKhan Rasool
May 27, 1986·European Journal of Pharmacology·S D BrainT J Williams
Jun 22, 1988·European Journal of Pharmacology·H NakamuraT Kadokawa
Apr 10, 1991·European Journal of Pharmacology·S H Peers, R J Flower
Sep 5, 1995·European Journal of Pharmacology·A AhluwaliaR J Flower
Apr 22, 1996·European Journal of Pharmacology·H CambridgeS D Brain
Sep 1, 1992·Toxicon : Official Journal of the International Society on Toxinology·E AntunesG de Nucci
Nov 1, 1993·Toxicon : Official Journal of the International Society on Toxinology·E AntunesG de Nucci
Feb 1, 1995·Toxicon : Official Journal of the International Society on Toxinology·A C BentoE Antunes
Jan 1, 1981·Prostaglandins·A W Ford-HutchinsonM J Smith
Feb 1, 1984·Prostaglandins·T TeranoS Moncada
Oct 1, 1996·Parasitology Today·A S BowmanJ R Sauer
Jan 1, 1983·International Journal of Immunopharmacology·J F Regal, R J Pickering
Aug 1, 1983·Prostaglandins, Leukotrienes, and Medicine·J MorleyC Gandolfi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.